Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...

In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can ...

Experts say the RSV vaccines were rigorously tested and the benefits of the ... As with any vaccine or medicine, there is ...

(Alliance News) - GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy respiratory syncytial virus vaccine to include adults aged 50 to 59 ...

Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease: London, UK Saturday, November 23, ...

Cases of RSV and flu are ticking up among young children in the U.S. even as overall respiratory virus activity remains low, ...

The latest health news includes the tragic death of two Australians from methanol poisoning in Laos, approval of GSK's RSV ...

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...

GSK's RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagious virus that affects ...

(Alliance News) - GSK PLC said on Friday that Japan's Ministry of Health, Labour & Welfare has approved the expansion of its Arexvy respiratory syncytial virus vaccine to include adults aged 50 to ...